Chimera Investment Corp has a consensus price target of $8.2 based on the ratings of 5 analysts. The high is $15 issued by Keefe, Bruyette & Woods on July 10, 2024. The low is $5.5 issued by UBS on December 6, 2023. The 3 most-recent analyst ratings were released by Keefe, Bruyette & Woods, UBS, and Credit Suisse on July 10, 2024, December 6, 2023, and May 19, 2023, respectively. With an average price target of $8.67 between Keefe, Bruyette & Woods, UBS, and Credit Suisse, there's an implied -42.18% downside for Chimera Investment Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/10/2024 | Buy Now | 0.07% | Keefe, Bruyette & Woods | Bose George | $15 → $15 | Maintains | Market Perform | Get Alert |
12/06/2023 | Buy Now | -63.31% | UBS | Douglas Harter | → $16.5 | Initiates | → Neutral | Get Alert |
05/19/2023 | Buy Now | -63.31% | Credit Suisse | Douglas Harter | $19.5 → $16.5 | Maintains | Neutral | Get Alert |
05/17/2023 | Buy Now | -59.97% | RBC Capital | Kenneth Lee | $21 → $18 | Maintains | Outperform | Get Alert |
05/09/2023 | Buy Now | -63.31% | Keefe, Bruyette & Woods | Bose George | $18.75 → $16.5 | Maintains | Market Perform | Get Alert |
04/24/2023 | Buy Now | -58.31% | Keefe, Bruyette & Woods | Bose George | $21 → $18.75 | Maintains | Market Perform | Get Alert |
03/09/2023 | Buy Now | -56.64% | Credit Suisse | Douglas Harter | → $19.5 | Reiterates | → Neutral | Get Alert |
03/07/2023 | Buy Now | -53.3% | RBC Capital | Kenneth Lee | → $21 | Reiterates | → Outperform | Get Alert |
10/05/2022 | Buy Now | -53.3% | RBC Capital | Kenneth Lee | $33 → $21 | Maintains | Outperform | Get Alert |
07/18/2022 | Buy Now | -39.96% | Barclays | Mark Devries | $33 → $27 | Maintains | Underweight | Get Alert |
05/23/2022 | Buy Now | -26.62% | RBC Capital | Kenneth Lee | $45 → $33 | Maintains | Outperform | Get Alert |
04/27/2022 | Buy Now | -26.62% | Barclays | Mark Devries | $42 → $33 | Maintains | Underweight | Get Alert |
01/10/2022 | Buy Now | -6.6% | Barclays | Mark Devries | $33 → $42 | Maintains | Underweight | Get Alert |
The latest price target for Chimera Investment (NYSE:CIM) was reported by Keefe, Bruyette & Woods on July 10, 2024. The analyst firm set a price target for $15.00 expecting CIM to rise to within 12 months (a possible 0.07% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Chimera Investment (NYSE:CIM) was provided by Keefe, Bruyette & Woods, and Chimera Investment maintained their market perform rating.
There is no last upgrade for Chimera Investment
There is no last downgrade for Chimera Investment.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chimera Investment, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chimera Investment was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
While ratings are subjective and will change, the latest Chimera Investment (CIM) rating was a maintained with a price target of $15.00 to $15.00. The current price Chimera Investment (CIM) is trading at is $14.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.